The role of tissue-resident memory T cells as mediators for response and toxicity in immunotherapy-treated melanoma—two sides of the same coin?
Robin Reschke(German Cancer Research Center), Jessica C. Hassel(German Cancer Research Center)
Cited by 16
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
|JAMA Oncology|2015|656